Why the study?
To analyze the effects of ARBs (Losartan, Telmisartan, or Candesartan) on levels of Ang III and LEP, and characterize the relationship between the two factors in rabbits.
Do angiotensin receptor blockers reduce Angiotensin III and Leptin levels in male rabbits?
Do angiotensin receptor blockers reduce Angiotensin III and Leptin levels in male rabbits?
Angiotensin receptor blockers significantly decrease Angiotensin III and Leptin levels in rabbits, suggesting an additional mechanism for their efficacy in treating cardiovascular illnesses.
Animal data on ARB effects on Ang III and leptin remain preliminary; human studies required before clinical relevance.
Angiotensin III (Ang III) properties include chemotaxis, creation development factors, and chemokines, which are also involved in renal and cardiovascular functions. Angiotensin receptor blockers (ARBs) are commonly used to treat cardiovascular illnesses. One factor that contributes to controlling blood pressure and resting metabolic rate is the protein Leptin (LEP). This study aimed to analyze ARB's (Losartan, Telmisartan, or Candesartan) effects on the levels of Ang III and LEP in rabbits. The characterization of the relationship between the two factors will be studied. The study was conducted on forty Oryctolagus cuniculus male rabbits. They were divided into four groups, randomly. Treated daily for ten days with intraperitoneal Losartan 0.7 mg/kg/day [G I], Telmisartan 0.6 mg/kg/day [G II], Candesartan 0.1 mg/kg/day [G III], and Control [G IV]. Pre- and post-treatment levels of Ang III and LEP, the changes in their histopathological characteristics, and coefficient correlations were analyzed. The three groups exhibited a drastic decrease in serum Ang III and LEP levels compared to the baseline and control. The effects of Losartan, Telmisartan, and Candesartan on the end organs of the liver, kidney, and heart, did not show any alterations. There was a weak positive correlation between the two factors. In conclusion; Losartan, Telmisartan, and Candesartan significantly decreased the activity of the RAS via their effect on Ang III and LEP levels as another mechanism for their efficacy in treating cardiovascular illnesses.
No takes yet. Share an insight, caveat, or question.
Al-Khalaf et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: